More articles from Review

  • Lipid-lowering: Can ezetimibe help close the treatment gap?
    Ryan C. Neal, MD and Peter H. Jones, MD
    Cleveland Clinic Journal of Medicine September 2003, 70 (9) 777-783;

    Ezetimibe (Zetia) is an important new drug for lowering cholesterol and may help overcome some of the barriers to reaching therapeutic goals.

  • Acne vulgaris: One treatment does not fit all
    Sharon J. Longshore, RPH, MD and Kimberly Hollandsworth, MD
    Cleveland Clinic Journal of Medicine August 2003, 70 (8) 670-680;

    With a variety of topical and oral agents available, the choice of therapy can range from simple and straightforward to intense and complex.

  • Treat high blood pressure sooner: Tougher, simpler JNC 7 guidelines
    Donald G. Vidt, MD and Raymond A. Borazanian, BS
    Cleveland Clinic Journal of Medicine August 2003, 70 (8) 721-728;

    In 2003, a blood pressure of 120/80 isn’t normal anymore—it’s prehypertensive.

  • Hair loss: Diagnosis and management
    Fabiane Mulinari-Brenner, MD and Wilma F. Bergfeld, MD
    Cleveland Clinic Journal of Medicine August 2003, 70 (8) 705-712;

    Alopecia is distressing, and we should not underestimate its importance, either as a cosmetic problem or as a sign of a potentially serious underlying condition.

  • Coronary imaging: Angiography shows the stenosis, but IVUS, CT, and MRI show the plaque
    Coronary imaging: Angiography shows the stenosis, but IVUS, CT, and MRI show the plaque
    Paul Schoenhagen, MD, Richard D. White, MD, Steven E. Nissen, MD and E. Murat Tuzcu, MD
    Cleveland Clinic Journal of Medicine August 2003, 70 (8) 713-719;

    New imaging tests can reveal information about coronary artery disease that traditional angiography cannot.

  • Update on contraception: Benefits and risks of the new formulations
    Pelin Batur, MD, Julie Elder, DO and Mark Mayer, MD
    Cleveland Clinic Journal of Medicine August 2003, 70 (8) 681-695;

    We review the new options, with emphasis on the Yasmin pill, the Lunelle injection, the Ortho Evra patch, the NuvaRing, the Mirena IUD, and emergency contraceptive kits.

  • Amiodarone-induced thyrotoxicosis: Diagnostic and therapeutic strategies
    Gustavo A. Cardenas, MD, José M. Cabral, MD and Camilo A. Leslie, MD, MBA
    Cleveland Clinic Journal of Medicine July 2003, 70 (7) 624-631;

    It is difficult but important to distinguish the two types of amiodarone-induced thyrotoxicosis.

  • New advances transform the management of women with abnormal Pap tests
    Xian Wen Jin, MD, PhD, Craig Nielsen, MD, Jennifer Brainard, MD and Belinda Yen-Lieberman, PhD
    Cleveland Clinic Journal of Medicine July 2003, 70 (7) 641-648;

    We review the new thin-layer slide system, the new HPV test, the 2001 reporting system for Pap tests, and new management guidelines.

  • Managing weight gain as a side effect of antidepressant therapy
    Rashmi Deshmukh, MD and Kathleen Franco, MD
    Cleveland Clinic Journal of Medicine July 2003, 70 (7) 314-623;

    Some drugs are more apt to cause weight gain than others; one should inform and work with the patient.

  • Using C-reactive protein to assess cardiovascular disease risk
    Mehdi H. Shishehbor, DO, Deepak L. Bhatt, MD and Eric J. Topol, MD
    Cleveland Clinic Journal of Medicine July 2003, 70 (7) 634-640;

    CRP is now a recognized cardiac test. But who should he tested?

Pages